4.7 Article

Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 1, 页码 88-127

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00875

关键词

-

资金

  1. National Institutes of Health [R21 MH093844, R01 DA038446, K05 DA020087, P30 DA28821, T32 DA07287, F31 DA045511]
  2. R. A. Welch Foundation Chemistry and Biology Collaborative Grant from the Gulf Coast Consortia (GCC)
  3. Center for Addiction Research (CAR) at UTMB
  4. John Sealy Memorial Endowment Fund

向作者/读者索取更多资源

G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据